glp-1 drugs and crohn's disease Primer: The Skinny on GLP-1s Recommendations for the safe and

Purpose of Review GLP-1 receptor agonists (GLP-1RAs) have become central therapies for obesity and metabolic disease

The Food and Drug Administration (FDA) on Friday announced that semaglutide, the active ingredient in weight loss drugs Ozempic and Wegovy, is no longer in short supply. | The demand for weight loss drugs is not slowing down, and many organizations voiced concerns there will likely be semaglutide shortages in the future that will impact patients' access to weight loss medications.

Heres how the program works, whats included, and who may qualify.

Explore GLP-1 medications like Ozempic and Wegovy

Updated June 2026